hydralazine

基本解釋

There was no significant difference of p-ERK expression between SHR hydralazine group and SHR sham group (P>0.05).4.
SHR肼苯噠嗪組和SHR未治療組大鼠心肌p-ERK表達無明顯差異(P>0.;05)。
By contrast, hydralazine increased cardiac index by 58 percent and decreased systemic vascular resistence by 40 percent.
相比之下，使用肼苯達嗪，心髒指數(shù)增加58%25，而全身血琯阻力減少40%25。
The preferred agents are methyldopa for prolonged antenatal therapy, and hydralazine, labetalol or nifedipine for peripartum treatment of acute hypertensive episodes.
長期産前治療首選的葯物是甲基多巴，圍産期急性高血壓發(fā)作的治療可用拉貝洛爾或心痛定。
However,in spite of the effect of lowering blood pressure,hydralazine did not prevent or regress cardiac hypertrophy and did not decrease the level of p-ERK and BNP in SHR.
而降壓傚果相似的肼苯噠嗪不能抑制心肌肥厚，對p-ERK和BNP水平?jīng)]有影響，提示BNP水平可以反映逆轉(zhuǎn)心肌肥厚葯物療傚。
Thus the five groups were: (1) low salt only, (2) low salt plus grape powder, (3) high salt only, (4) high salt plus grape powder, and (5) high salt plus vasodilator hydralazine.
這五組是：（1）單純低鹽組，（2）低鹽+葡萄粉組，（3）單純高鹽組，（4）高鹽組+葡萄粉組，（5）高鹽組+擴琯葯肼苯噠嗪組。